Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine

Regina Rendas-Baum, Min Yang, Sepideh F Varon, Lisa M Bloudek, Ronald E DeGryse, Mark Kosinski, Regina Rendas-Baum, Min Yang, Sepideh F Varon, Lisa M Bloudek, Ronald E DeGryse, Mark Kosinski

Abstract

Background: The Headache Impact Test (HIT)-6 was developed and has been validated in patients with various types of headache. The objective of this study was to report the psychometric properties of the HIT-6 among patients with chronic migraine.

Methods: Data came from two international, multicenter, randomized, double-blind, placebo-controlled clinical trials of chronic migraine patients (N = 1,384) undergoing prophylaxis therapy. Confirmatory factor analysis and differential item functioning (DIF) analysis were used to test the latent structure and cross-cultural comparability of the HIT-6. Reliability, construct validity, and responsiveness were assessed. Two sets of criterion groups were used: (1) 28-day headache frequency: <10, 10-14, and ≥15 days; (2) sample quartiles of the total cumulative hours of headache: <140, 140 to <280, 280 to <420, and ≥420 hours. Two sets of responsiveness categories were defined as reduction of <30%, 30% to <50%, or ≥50% in (1) number of headache days and (2) cumulative hours of headache.

Results: Measurement invariance tests supported the stability of the HIT-6 latent structure across studies. DIF analysis supported cross-cultural comparability. Good reliability was observed across studies (Cronbach's α: 0.75-0.92; intraclass correlation coefficient: 0.76-0.80). HIT-6 scores correlated strongly (-0.86 to -0.59) with scores of the Migraine-Specific Quality-of-Life Questionnaire. Analysis of variance indicated that HIT-6 scores discriminated across both types of criterion groups (P<0.001), across studies and time points. HIT-6 change scores were significantly higher in magnitude in groups experiencing greater improvement (P<0.001).

Conclusion: All measurement properties were consistently verified across the two studies, supporting the validity of the HIT-6 among chronic migraine patients.

Trial registration: NCT00156910 and NCT00168428 on www.ClinicalTrials.gov.

References

    1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–349. doi: 10.1212/01.wnl.0000252808.97649.21.
    1. Rasmussen BK. Epidemiology of migraine. Biomed Pharmacother. 1995;49:452–455. doi: 10.1016/0753-3322(96)82689-8.
    1. Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology. 2009;72:S3–S7. doi: 10.1212/WNL.0b013e3181974b19.
    1. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157–1168. doi: 10.1111/j.1526-4610.2008.01217.x.
    1. Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache. 2008;48:7–15. doi: 10.1111/j.1526-4610.2007.00969.x.
    1. Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71:848–855. doi: 10.1212/01.wnl.0000325565.63526.d2.
    1. Holroyd KA. Assessment and psychological management of recurrent headache disorders. J Consult Clin Psychol. 2002;70:656–677. doi: 10.1037/0022-006X.70.3.656.
    1. Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28:484–495. doi: 10.1111/j.1468-2982.2008.01555.x.
    1. Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C, Sandrini G, Steiner T, Winter PB. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20:765–786. doi: 10.1046/j.1468-2982.2000.00117.x.
    1. Kosinski M, Bayliss MS, Bjorner JB, Ware JE, Jr, Garber WH, Batenhorst A, Cady R, Dahlof CG, Dowson A, Tepper S. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12:963–974. doi: 10.1023/A:1026119331193.
    1. Kawata AK, Coeytaux RR, Devellis RF, Finkel AG, Mann JD, Kahn K. Psychometric properties of the HIT-6 among patients in a headache-specialty practice. Headache. 2005;45:638–643. doi: 10.1111/j.1526-4610.2005.05130.x.
    1. Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol. 2006;59:374–380. doi: 10.1016/j.jclinepi.2005.05.010.
    1. De Hertogh W, Meiresone S, Wouters E, Cras P. A pilot study to assess the responsiveness of the headache impact test (HIT-6) [abstract] Cephalalgia. 2009;29:79.
    1. Usai S, Grazzi L, D’Amico D, Andrasik F, Bussone G. Reduction in the impact of chronic migraine with medication overuse after day-hospital withdrawal therapy. Neurol Sci. 2008;29(Suppl 1):S176–S178. doi: 10.1007/s10072-008-0918-1.
    1. Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the headache impact test (HIT-6) across episodic and chronic migraine. Cephalalgia. 2011;31:357–367. doi: 10.1177/0333102410379890.
    1. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803. doi: 10.1177/0333102410364676.
    1. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–814. doi: 10.1177/0333102410364677.
    1. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equ Model. 1999;6:1–55. doi: 10.1080/10705519909540118.
    1. Bayliss M, Batenhorst A. The HIT-6™ A User’s Guide. Lincoln, RI: QualityMetric Incorporated; 2002.
    1. Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract. 1996;42:36–42.
    1. Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the migraine-specific quality of life questionnaire. Headache. 1998;38:295–302. doi: 10.1046/j.1526-4610.1998.3804295.x.
    1. Millsap RE, Yun-Tein J. Assessing factorial invariance in ordered-categorical measures. Multivar Behav Res. 2004;39:479–515. doi: 10.1207/S15327906MBR3903_4.
    1. Asparouhov T, Muthen B: Robust Chi square difference testing with mean and variance adjusted test statistics.MPlus Web Notes 2006, .
    1. Muthen LD, Muthen BO. MPlus User’s Guide. Los Angeles, CA: Muthen & Muthen; 2007.
    1. Crane PK, Gibbons LE, Jolley L, van Belle G. Differential item functioning analysis with ordinal logistic regression techniques. DIFdetect Difwithpar Med Care. 2006;44:S115–S123. doi: 10.1097/01.mlr.0000245183.28384.ed.
    1. Millsap RE, Everson HT. Methodology review: statistical approaches for assessing measurement bias. Appl Psychol Meas. 1993;17:297–334. doi: 10.1177/014662169301700401.
    1. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138:923–936.
    1. Stokes ME, Davis CS, Koch GG. Categorical Analysis Using the SAS System. 2. Cary, NC: SAS Institute Inc.; 2000.
    1. Fleiss JL. Design and Analysis of Clinical Experiments. New York: John Wiley & Sons; 1986.
    1. Anastasi A, Urbina S. Psychological Testing. Upper Saddle River, NJ: Prentice Hall; 1997.
    1. Nunnally JC, Bernstein IH. Psychometric Theory. New York: McGraw-Hill; 1994.
    1. Clark LA, Watson D. Constructing validity: basic issues in objective scale development. Psychol Assess. 1995;7:309–319. doi: 10.1037/1040-3590.7.3.309.
    1. Kerlinger F. Foundations of Behavioral Research. New York: Holt, Rinehart & Winston; 1973.
    1. Lipton RB, Bigal ME. Looking to the future: research designs for study of headache disease progression. Headache. 2008;48:58–66. doi: 10.1111/j.1526-4610.2007.00976.x.
    1. Cohen JA, Beall DG, Miller DW, Beck A, Pait G, Clements BD. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med. 1996;28:171–177.
    1. Scott NW, Fayers PM, Aaronson NK, de Bottomley A GA, Groenvold M, Gundy C, Koller M, Petersen MA, Sprangers MA. A simulation study provided sample size guidance for differential item functioning (DIF) studies using short scales. J Clin Epidemiol. 2009;62:288–295. doi: 10.1016/j.jclinepi.2008.06.003.
    1. O’Connell A. Logistic Regression Models for Ordinal Response Variables. Thousand Oaks, CA: SAGE Publications; 2006.
    1. Brant R. Assessing proportionality in the proportional odds model for ordinal logistic regression. Biometrics. 1990;46:1171–1178. doi: 10.2307/2532457.
    1. Martin M, Blaisdell B, Kwong JW, Bjorner JB. The short-form headache impact test (HIT-6) was psychometrically equivalent in nine languages. J Clin Epidemiol. 2004;57:1271–1278. doi: 10.1016/j.jclinepi.2004.05.004.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren